Testing a blood test to predict immunotherapy response
Part of Cancer, Skin clinical trials.
This study is testing a new blood test called IOpener®-Melanoma to see if it can predict which patients with advanced melanoma will respond well to immunotherapy. The goal is to better match treatments to people who will benefit most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (stage III or IV) that cannot be removed with surgery.
- You are about to start your first immunotherapy (either nivolumab, pembrolizumab, or nivolumab plus ipilimumab).
- You have not taken BRAF/MEK inhibitors (targeted therapy) for advanced melanoma.
- If you had immunotherapy after surgery, you finished it at least 6 months ago.
- Your brain metastases (if any) are not causing symptoms or growing.
- You are in good enough health to go about daily activities (WHO performance score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
This study looks at how melanoma cells “use energy” (tumor metabolism) to understand why immunotherapy can become less effective over time. If you are starting immunotherapy for advanced skin melanoma, the results may help improve future treatments for resistance.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This trial tests a new drug, OPM-101, combined with an immunotherapy drug (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.